Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: Bart O. Roep Clear advanced filters
  • In this Opinion article, the authors suggest that more extensive use of laboratory measurements could help to expedite clinical trials of immunotherapy. They propose that surrogate end points could be used in place of clinical end points to determine drug safety, disease progression and therapeutic efficacy.

    • Bart O. Roep
    • Mark Peakman
    Reviews
    Nature Reviews Immunology
    Volume: 10, P: 145-152
  • Researchers have now probably pinpointed all the genes in the MHC genomic region that are risk factors in type 1 diabetes. As the MHC is unusually rich in genes involved in immunity, this is truly exciting.

    • Bart O. Roep
    News & Views
    Nature
    Volume: 450, P: 799-800
  • Attempts to prevent type 1 diabetes mellitus have been limited to interventions in patients who have already lost immune tolerance to pancreatic β cells. However, in a new report, orally administered insulin initiates immune protection in young children at increased risk of the disease.

    • Bart O. Roep
    News & Views
    Nature Reviews Endocrinology
    Volume: 11, P: 451-452
  • The newly appreciated heterogeneity in type 1 diabetes mellitus implies that a personalized approach could be used to treat this disease; treatments that modify the immune system might be ideally suited to this purpose. This Review discusses the current knowledge on immune regulation and dysfunction in humans that could be used to develop new therapies.

    • Bart O. Roep
    • Timothy I. M. Tree
    Reviews
    Nature Reviews Endocrinology
    Volume: 10, P: 229-242
  • Use of an alternative open reading frame, potentially as a result of cellular stress, drives production of an unconventional insulin epitope that is recognized by cytotoxic T cells from individuals with type 1 diabetes; these T cells kill beta cells in vitro.

    • Maria J L Kracht
    • Menno van Lummel
    • Bart O Roep
    Research
    Nature Medicine
    Volume: 23, P: 501-507
  • Enteroviral infection persistence as determined by host genetic susceptibility, rather than independent, short-lived infections, may contribute to islet autoimmunity and be a precursor to the development of type 1 diabetes.

    • Bart O. Roep
    News & Views
    Nature Medicine
    Volume: 25, P: 1816-1818
  • Translational research in autoimmunity is hampered by a number of hurdles, including a lack of knowledge regarding initiating and pathologically relevant autoantigens, the low frequency of autoreactive pathogenic B and T cells, difficulty in accessing the affected tissue, differences between self-reactive and pathogen-specific lymphocytes, a lack of etiologically relevant preclinical animal models and the heterogeneity of disease presentation. Given the need for biomarkers and new therapeutics, it is imperative that these hurdles be surmounted.

    • Bart O Roep
    • Jane Buckner
    • Frauke Zipp
    Comments & Opinion
    Nature Medicine
    Volume: 18, P: 48-53
  • This Review examines the evidence that β-cells are active participants in the dialogue with the immune system during the development of type 1 diabetes mellitus. The authors suggest that therapies targeting β-cell health, vitality and function might prove essential, in combination with immunotherapy, to change the course of events leading to β-cell destruction.

    • Bart O. Roep
    • Sofia Thomaidou
    • Arnaud Zaldumbide
    Reviews
    Nature Reviews Endocrinology
    Volume: 17, P: 150-161